Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

This study is testing a combination of three drugs — zanzalintinib (which targets blood vessel growth in tumors), ipilimumab, and nivolumab (both immune checkpoint inhibitors) — for people with soft tissue sarcoma that has spread or cannot be removed surgically. **You may be eligible if...** - You have been diagnosed with soft tissue sarcoma confirmed by biopsy or lab analysis, and it has spread or cannot be surgically removed - You have already received between 1 and 3 prior treatments for advanced disease and your cancer has progressed - Your overall health is good enough to tolerate treatment (measured by standard performance criteria) - Your organ function (kidneys, liver, blood counts) is within acceptable ranges **You may NOT be eligible if...** - You have certain types of sarcoma that respond to other specific treatments (such as GIST or Ewing sarcoma, depending on protocol) - You have active autoimmune disease requiring systemic treatment - You have uncontrolled brain metastases - You have had prior immune checkpoint therapy and experienced severe side effects - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.